Guangdong Jiaying Pharmaceutical Co., Ltd
Simbolis: 002198.SZ
SHZ
6.73
CNYRinkos kaina šiandien
121.8232
P/E santykis
10.9641
PEG koeficientas
3.42B
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Guangdong Jiaying Pharmaceutical Co., Ltd (002198-SZ) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1231.73 | 334 | 234.1 | 239.4 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 660.9 | 200.5 | 50.3 | 0 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 657.68 | 154 | 240.6 | 175.7 | ||||||||||||||||||||
balance-sheet.row.inventory | 347.58 | 84.6 | 82.3 | 73.4 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 5.96 | 1.1 | 0.4 | 1.2 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 2267.86 | 580.2 | 557.4 | 489.7 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 769.11 | 190.4 | 203.7 | 224.2 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 191.46 | 47.2 | 52.4 | 58.3 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 191.46 | 47.2 | 52.4 | 58.3 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | -134.09 | 27.1 | -20.9 | 30.6 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 8.72 | 2.2 | 2.2 | 4.6 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 240.92 | 0.5 | 51.8 | 0 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 1076.11 | 267.4 | 289.2 | 317.7 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 3343.97 | 847.6 | 846.7 | 807.3 | ||||||||||||||||||||
balance-sheet.row.account-payables | 42.13 | 9.2 | 19 | 14.1 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | -2.03 | 0 | 5.8 | 31.1 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 28.03 | 7.5 | 17.2 | 12 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||||||
Deferred Revenue Non Current | 1.72 | 0.4 | 0.5 | 0.2 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 139.12 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 118.62 | 40.2 | 47.1 | 5.7 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 140.84 | 35.2 | 35.3 | 34.9 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-liab | 315.92 | 84.6 | 118.2 | 122.9 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 54.45 | 27.2 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 2030.04 | 507.5 | 507.5 | 507.5 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 398.09 | 104.6 | 70.3 | 26.3 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 174.76 | 0 | 27.2 | 27.2 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 370.71 | 123.7 | 123.4 | 123.4 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 3028.05 | 763 | 728.4 | 684.5 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 3343.97 | 847.6 | 846.7 | 807.3 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-equity | 3028.05 | 763 | 728.4 | 684.5 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 3343.97 | - | - | - | ||||||||||||||||||||
Total Investments | 105.91 | 27.1 | 29.4 | 30.6 | ||||||||||||||||||||
balance-sheet.row.total-debt | 5.87 | 0 | 5.8 | 31.1 | ||||||||||||||||||||
balance-sheet.row.net-debt | -564.95 | -133.5 | -178.1 | -208.3 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 27.32 | 43.9 | 1.5 | 19.8 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 18.01 | 25.9 | 28.4 | 28.2 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 2.4 | 1 | -0.6 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -2.4 | -1 | 0.6 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | 116.01 | -48.4 | -4.8 | 38.8 | |||||||||||||||||||
cash-flows.row.account-receivables | 118.37 | -86.5 | 9.6 | 9 | |||||||||||||||||||
cash-flows.row.inventory | -2.36 | -8.4 | -0.8 | 2.5 | |||||||||||||||||||
cash-flows.row.account-payables | 0 | 44.1 | -14.7 | 27.9 | |||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 2.4 | 1 | -0.6 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | -48.06 | 5.7 | 26.7 | 10 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 113.28 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -12.26 | -2.7 | -2.3 | -11.7 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 141.97 | 0.1 | 0 | 0 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -0.1 | 0 | 0 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | -126.83 | 1.6 | 32.5 | 18.5 | |||||||||||||||||||
cash-flows.row.other-investing-activites | -180 | -49.9 | 25.1 | -25 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -176.93 | -51 | 55.2 | -18.2 | |||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -31.1 | -15 | -135 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | -0.5 | -1 | -3.8 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 31.1 | 55 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -31.6 | 15.1 | -83.8 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | -64.89 | -55.4 | 122.1 | -5.1 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 567.95 | 183.9 | 239.3 | 117.2 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 632.85 | 239.3 | 117.2 | 122.3 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 113.28 | 27.2 | 51.8 | 96.9 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -12.26 | -2.7 | -2.3 | -11.7 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 101.02 | 24.4 | 49.5 | 85.2 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 499.15 | 533.2 | 659.2 | 574.7 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 184.54 | 185.5 | 228.5 | 141.9 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 314.61 | 347.7 | 430.7 | 432.8 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 10.47 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 13.37 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 219.49 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | -1.19 | -1.1 | 40.7 | 46.3 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 285.61 | 310.4 | 376 | 403.2 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 470.15 | 495.9 | 604.5 | 545.1 | ||||||||||||||||||||
income-statement-row.row.interest-income | 2.17 | 2.1 | 2.3 | 2.6 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0.5 | 1 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 219.49 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0.14 | 2.1 | -2.8 | -27.8 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | -1.19 | -1.1 | 40.7 | 46.3 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0.14 | 2.1 | -2.8 | -27.8 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0.5 | 1 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 8.91 | 24.2 | 26.6 | 28.4 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 30.17 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 33.65 | 40.5 | 53.9 | 33.6 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 32.46 | 39.4 | 51.1 | 5.8 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 5.15 | 5.1 | 7.2 | 4.3 | ||||||||||||||||||||
income-statement-row.row.net-income | 27.32 | 34.3 | 43.9 | 1.5 |
Dažnai užduodami klausimai
Kas yra Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) bendras turtas?
Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) bendras turtas yra 847563113.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 250417163.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.630.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 0.199.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.055.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.067.
Kas yra Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 34320234.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 0.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 310409681.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 118503980.000.